Uncomplicating Diabetes: Reducing the Burden of Diabetes Related End-Organ Injury

摘要 请求支持题为《无并发症糖尿病：减少 糖尿病相关终末器官损伤的负担，由马克·E·库珀博士、托马斯·M·科夫曼博士组织， 马蒂亚斯·冯·赫拉斯和苏珊·夸金。大会将于2018年2月25日至3月1日在 新墨西哥州圣达菲。 这次Keystone研讨会将讨论糖尿病并发症，这些并发症仍然是糖尿病的主要原因 糖尿病人群的发病率和死亡率。尽管在过去的二十年里，前景有所改善 对于糖尿病血管疾病，这些并发症仍然是潜在的主要负担。 这些并发症在分子和细胞水平上的解释尚未完全阐明。 随着糖尿病治疗的最新进展，特别是新型降糖剂，它是 关键是要确定这些新疗法是否既有葡萄糖依赖又有独立的降低血糖的效果 糖尿病相关的终末器官损伤。随着我们对主要病理特征的理解取得重大进展 糖尿病并发症，如血管生成、纤维化、炎症和血管重构，尽管在非糖尿病 在糖尿病的背景下，现在是时候将这一新知识转化为糖尿病并发症领域。通过 向糖尿病并发症领域学习和招募这样的研究人员，有很大的意义 有机会开发新的、高度创新的方法来确定新的目标，以发现新的 治疗、逆转或预防糖尿病并发症的方法，这些并发症导致过早的动脉粥样硬化、心力衰竭、 失明、认知障碍和终末期肾病。

ABSTRACT Support is requested for a Keystone Symposia conference entitled Uncomplicating Diabetes: Reducing the Burden of Diabetes Related End-Organ Injury, organized by Drs. Mark E. Cooper, Thomas M. Coffman, Matthias G. von Herrath and Susan Quaggin. The conference will be held February 25 - March 1, 2018 in Santa Fe, New Mexico. This Keystone Symposia conference will address diabetic complications which remain the major cause of morbidity and mortality in the diabetic population. Although the outlook has improved over the last two decades with respect to diabetic vascular disease, these complications remain a major burden with the underlying explanation for these complications at a molecular and cellular level as yet not fully clarified. With recent advances in the management of diabetes, particularly new classes of glucose-lowering agents, it is critical to determine if these new therapies have both glucose-dependent and independent effects in reducing diabetes-related end-organ injury. With major advances in our understanding of key pathological features of diabetic complications such as angiogenesis, fibrosis, inflammation and vascular remodeling, albeit in non- diabetic contexts, now is the time to translate this new knowledge to the field of diabetic complications. By learning from and recruiting such researchers into the field of diabetic complications, there is a great opportunity to develop novel, highly innovative approaches to identify new targets in order to discover new ways to treat, reverse or prevent diabetic complications that lead to premature atherosclerosis, heart failure, blindness, cognitive impairment and end-stage renal disease.